Kahn Swick & Foti, LLC (KSF) has notified investors of a class action securities lawsuit against LKQ Corporation (NASDAQ: LKQ). The lawsuit alleges securities fraud between February 27, 2023, and July 23, 2025, stemming from misrepresentations regarding LKQ's acquisition and integration of FinishMaster. Investors who suffered losses have until June 22, 2026, to apply for lead plaintiff status.

This article highlights Gina Beredo, Executive Vice President, General Counsel, and Secretary at Nordson Corp., as one of the "Women of Note 2019" by Crain's Cleveland Business. The brief entry mentions her role and the recognition she received in 2019.

Jin Zhao, President of Diodes Asia, sold 2,760 shares of Diodes Inc (DIOD) on May 12, 2026, reducing his holdings to 32,100 shares. This transaction is part of a trend of 18 insider sells and no buys over the past year for the company. Diodes Inc is currently trading at $102.36, indicating it is significantly overvalued with a price-to-GF-Value ratio of 1.54 compared to its intrinsic GF Value of $66.37.

Brett Whitmire, CFO of a Diodes Inc (DIOD) subsidiary, sold 16,556 shares of the company on May 13, 2026. This transaction follows a total of 18 insider sales and no insider buys at Diodes Inc over the past year. The stock is currently trading at $103.34, which is significantly above its GF Value of $66.37, indicating it is overvalued.

Marriott International director Grant Reid was granted 670 deferred Class A shares at a price of $0.00 per share, increasing his direct holdings to 3,518 shares. This award is part of a director deferred stock compensation plan and will vest daily pro-rata over twelve months, with distribution occurring after his service as a Board member ends. This transaction was a grant, not an open-market purchase, and is detailed in a recent SEC Form 4 filing.

Valero Energy Corporation (VLO) has significantly outperformed the broader market and the energy sector over the past year, with its stock rallying 80.9%. The company recently reported Q1 results that exceeded analyst expectations, showing a 7% year-over-year revenue growth and higher-than-anticipated EPS. Wall Street analysts maintain a "Moderate Buy" consensus rating for VLO, with a mean price target suggesting a modest upside from current levels, and some analysts predicting a potential upside of over 22%.

The European Commission has approved Pfizer's HYMPAVZI (marstacimab) to expand its indication for adults and adolescents aged 12 and older with hemophilia A or B who have inhibitors. This once-weekly subcutaneous treatment demonstrated superior bleed reduction compared to on-demand therapy in Phase 3 trials and is the only medicine approved in the EU for both hemophilia A and B with or without inhibitors. The approval provides a new critical treatment option for patients whose traditional factor replacement therapies are ineffective due to inhibitor development.

Mid-America Technology Center (MATC) has recognized CVR Energy, Inc. as its 2026 Partner in Progress, honoring the company's commitment to workforce development, community partnership, and educational advancement. CVR Energy has played a vital role in MATC's Professional Resource Outreach programs, notably contributing $80,000 in 2025 to launch the CVR Energy, Inc. District 8 Hub Store, which provides essential support to students facing financial barriers. This partnership exemplifies a strong collaboration that drives progress in the Mid-America district.

This article provides financial information for Cullen/Frost Bankers, Inc. Depositary Shares (NYSE: CFR/PB), specifically focusing on the ratio of savings deposits to total deposits. It identifies the security as representing a 1/40th ownership interest in a share of 4.450% non-cumulative perpetual preferred stock, Series. The content is presented within the context of a financial data platform, highlighting market status and financial metrics.

Concord Healthcare Group Co., Ltd., a subsidiary of Concord Medical Services Holdings Ltd, has issued HK$68 million in 2% convertible bonds due 2027. The transaction involved Haitong International Securities Company Limited as the placing agent and Dragon Merit Holdings Limited as the subscriber. This issuance follows the listing of Concord Healthcare’s H shares on the Main Board of The Stock Exchange of Hong Kong Limited on January 9, 2024.